Last 12 months
Inside the activity.
1 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 1 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,068 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 12 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,472 Underlying: Common Stock · 1,068 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
OtherRestricted Stock Unit · Derivative | 1,332 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 11 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,298 Underlying: Common Stock · 1,332 shares Expires 2022-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
Exercise / conversionRestricted Stock Unit · Derivative | 964 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 10 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,630 Underlying: Common Stock · 964 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
OtherRestricted Stock Unit · Derivative | 1,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 9 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,005 shares Expires 2021-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
Exercise / conversionRestricted Stock Unit · Derivative | 891 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 8 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,005 Underlying: Common Stock · 891 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
Tax withholdingCommon Stock | 474 | $278.03 | $131,786.22 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 7 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,990.3603 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
Tax withholdingCommon Stock | 428 | $278.03 | $118,996.84 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 6 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,464.3603 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
Tax withholdingCommon Stock | 396 | $278.03 | $110,099.88 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 5 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,892.3603 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
Exercise / conversionCommon Stock | 1,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 4 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,288.3603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
Exercise / conversionCommon Stock | 964 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 3 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,220.3603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
Exercise / conversionCommon Stock | 891 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,256.3603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC |
Gregory GingerEVP, Human Resources
|
Tax withholdingCommon Stock | 884 | $278.03 | $245,778.52 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,365.3603 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon the vesting of shares, as previously disclosed by reporting person on January 29, 2021. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
OtherRestricted Stock Unit · Derivative | 1,298 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 14 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,522 Underlying: Common Stock · 1,298 shares Expires 2023-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Exercise / conversionRestricted Stock Unit · Derivative | 960 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 13 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,820 Underlying: Common Stock · 960 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
OtherRestricted Stock Unit · Derivative | 451 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 12 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784 Underlying: Common Stock · 451 shares Expires 2022-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Exercise / conversionRestricted Stock Unit · Derivative | 327 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 11 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,235 Underlying: Common Stock · 327 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
OtherRestricted Stock Unit · Derivative | 322 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 10 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 322 shares Expires 2021-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Exercise / conversionRestricted Stock Unit · Derivative | 286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · derivative · entry 9 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322 Underlying: Common Stock · 286 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Tax withholdingCommon Stock | 282 | $278.03 | $78,404.46 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 7 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,303.229 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Tax withholdingCommon Stock | 96 | $278.03 | $26,690.88 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 6 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,585.229 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Tax withholdingCommon Stock | 84 | $278.03 | $23,354.52 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 5 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,681.229 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Exercise / conversionCommon Stock | 960 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 4 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,765.229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Exercise / conversionCommon Stock | 327 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 3 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,805.229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Exercise / conversionCommon Stock | 286 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 2 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,478.229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:54 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Tax withholdingCommon Stock | 253 | $278.03 | $70,341.59 |
DisclosureSEC source: 0001127602-21-006267 · form4.xml · nonDerivative · entry 1 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,192.229 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon the vesting of shares, as previously disclosed by reporting person on January 29, 2021. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,367 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · derivative · entry 13 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,434 Underlying: Common Stock · 1,367 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
OtherRestricted Stock Unit · Derivative | 1,849 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · derivative · entry 12 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,801 Underlying: Common Stock · 1,849 shares Expires 2023-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,402 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · derivative · entry 11 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,344 Underlying: Common Stock · 1,402 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
OtherRestricted Stock Unit · Derivative | 1,936 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · derivative · entry 10 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,746 Underlying: Common Stock · 1,936 shares Expires 2022-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
OtherRestricted Stock Unit · Derivative | 1,788 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · derivative · entry 9 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,788 shares Expires 2021-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,586 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · derivative · entry 8 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,788 Underlying: Common Stock · 1,586 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Tax withholdingCommon Stock | 607 | $278.03 | $168,764.21 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · nonDerivative · entry 7 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,576 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Tax withholdingCommon Stock | 622 | $278.03 | $172,934.66 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · nonDerivative · entry 6 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,183 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Tax withholdingCommon Stock | 704 | $278.03 | $195,733.12 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · nonDerivative · entry 5 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,805 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Exercise / conversionCommon Stock | 1,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · nonDerivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Exercise / conversionCommon Stock | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · nonDerivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Exercise / conversionCommon Stock | 1,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:52 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Tax withholdingCommon Stock | 1,963 | $278.03 | $545,772.89 |
DisclosureSEC source: 0001127602-21-006261 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,154 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon the vesting of shares, as previously disclosed by reporting person on January 29, 2021. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 21:31 UTC |
Mantas Jesus BDirector
|
PurchaseCommon Stock | 898 | $267.00 | $239,766.00 |
DisclosureSEC source: 0001127602-21-004941 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,943 Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:47 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
GrantCommon Stock | 4,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002980 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,117 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2018. The shares will vest on February 12, 2021. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:45 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
GrantCommon Stock | 818 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002978 · form4.xml · nonDerivative · entry 1 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,445.229 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2018. The shares will vest on February 12, 2021. F2 · balance_after: Includes 84.965 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2020. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:44 UTC |
Gregory GingerEVP, Human Resources
|
GrantCommon Stock | 2,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002975 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,249.3603 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2018. The shares will vest on February 12, 2021. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:43 UTC |
Sandrock AlfredEVP, Research & Development
|
GrantCommon Stock | 3,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002974 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,794.2101 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2018. The shares will vest on February 12, 2021. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:41 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
GrantCommon Stock | 16,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002973 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,153.286 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2018. The shares will vest on February 12, 2021. Read SEC document |
| December 31, 2020 Filed Feb 9, 2021 21:14 UTC |
PANGIA ROBERT WDirector
|
GiftCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004675 · form5.xml · nonDerivative · entry 2 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,632 F1 · kind: Reporting person gifted shares to the Robin Drive, LLC (the "Trust"), of which his wife is Trustee, on December 31, 2020. Reporting person disclaims all beneficial ownership of the shares held by the Trust. Read SEC document |
| December 31, 2020 Filed Feb 9, 2021 21:14 UTC |
PANGIA ROBERT WDirector
|
GiftCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004675 · form5.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Robin Drive, LLC Disclosed balance after: 16,000 F1 · kind: Reporting person gifted shares to the Robin Drive, LLC (the "Trust"), of which his wife is Trustee, on December 31, 2020. Reporting person disclaims all beneficial ownership of the shares held by the Trust. Read SEC document |
| December 03, 2020 Filed Dec 8, 2020 02:08 UTC |
Kramer RobinVP, Chief Accounting Officer
|
OtherRestricted Stock Unit · Derivative | 102 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030793 · form4.xml · derivative · entry 4 Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178 Underlying: Common Stock · 102 shares Expires 2021-12-03 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| December 03, 2020 Filed Dec 8, 2020 02:08 UTC |
Kramer RobinVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 74 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030793 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280 Underlying: Common Stock · 74 shares Expires 2021-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| December 03, 2020 Filed Dec 8, 2020 02:08 UTC |
Kramer RobinVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 22 | $244.09 | $5,369.98 |
DisclosureSEC source: 0001127602-20-030793 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373.446 Read SEC document |
| December 03, 2020 Filed Dec 8, 2020 02:08 UTC |
Kramer RobinVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 74 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030793 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395.446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.